
Mucopolysaccharidosis (MPS): The MPSs comprise a group of 11 MPS types, each a monogenic disease due to a specific single enzyme defect, but all of which lead to primary glycosaminoglycan storage, other abnormal metabolic changes and storage products, and multiorgan pathologies. Neuropathology is a feature of a majority of the MPS types. We are seeking applications directed to treating the central nervous system manifestations, and other primary manifestations from MPS including cardio-respiratory disease and bone and connective tissue issues. One grant of \$60,350 is made possible by Team MPS and the National MPS Society.